Veeva Systems Strengthens MLR Solutions with Acquisition of Copli and Launch of Falcon MLR
On June 23, 2026, Veeva Systems, a publicly traded company known for innovative solutions in the life sciences industry, announced the acquisition of Copli, a company recognized as a leader in medical, legal, and regulatory (MLR) solutions. This strategic move marks a significant milestone for Veeva as it aims to launch the Veeva Falcon MLR, a cutting-edge solution that promises substantial advancements in content review processes.
With the implementation of Veeva Falcon MLR, Veeva Systems positions itself at the forefront of MLR transformation, promising to accelerate content review cycles by potentially removing over 70% of manual labor involved within the next five years. As a result, marketing teams, MLR groups, and agencies will benefit from agentic automation that streamlines the review of promotional and medical materials. The automated system will conduct compliance checks against approved labels and local regulations, thereby minimizing manual effort and allowing reviewers to focus on more strategic aspects of their roles.
Jacob Scheel-Bech, the CEO of Copli, stated, "Our breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval." He emphasized that, under Veeva's larger umbrella, the ambition for MLR transformation can be scaled more effectively.
Emma Hyland, Vice President of Veeva Commercial Content, echoed these sentiments, highlighting that the MLR review process has historically been a bottleneck for getting vital information to healthcare professionals and patients. Hyland believes that Veeva Falcon MLR will empower clients to expedite the entire review cycle, automating routine manual tasks and enabling reviewers to act as strategic advisors instead.
To further explore the features of Veeva Falcon MLR, interested parties are invited to a webinar scheduled for July 9 at 10 a.m. ET. For those who wish to seek more information immediately, they can visit FalconMLR.veeva.com.
Veeva Systems continues to lead the charge in providing industry cloud solutions for life sciences, utilizing innovative software, artificial intelligence, and consulting services. With over 1,500 clients, ranging from major pharmaceutical giants to emerging biotech firms, Veeva remains committed to the success of its customers alongside its public benefit objectives.
As with all acquisitions, Veeva acknowledges the associated risks and uncertainties, with Veeva CFO encouraging stakeholders to consult periodic SEC filings for detailed information regarding potential implications.
For further details, representatives from Veeva's communication team, Maria Scurry and Meera Lakhani-Patel, are available to discuss the broader impacts of this acquisition and rollout, establishing Veeva Falcon MLR as a revolutionary tool in the life sciences content review landscape.
Overall, with the merger of Veeva and Copli, the company is well poised to redefine the speed and efficiency of content review in the life sciences sector, solidifying its role as an integral player in the industry's future advancements.
With the implementation of Veeva Falcon MLR, Veeva Systems positions itself at the forefront of MLR transformation, promising to accelerate content review cycles by potentially removing over 70% of manual labor involved within the next five years. As a result, marketing teams, MLR groups, and agencies will benefit from agentic automation that streamlines the review of promotional and medical materials. The automated system will conduct compliance checks against approved labels and local regulations, thereby minimizing manual effort and allowing reviewers to focus on more strategic aspects of their roles.
Jacob Scheel-Bech, the CEO of Copli, stated, "Our breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval." He emphasized that, under Veeva's larger umbrella, the ambition for MLR transformation can be scaled more effectively.
Emma Hyland, Vice President of Veeva Commercial Content, echoed these sentiments, highlighting that the MLR review process has historically been a bottleneck for getting vital information to healthcare professionals and patients. Hyland believes that Veeva Falcon MLR will empower clients to expedite the entire review cycle, automating routine manual tasks and enabling reviewers to act as strategic advisors instead.
To further explore the features of Veeva Falcon MLR, interested parties are invited to a webinar scheduled for July 9 at 10 a.m. ET. For those who wish to seek more information immediately, they can visit FalconMLR.veeva.com.
Veeva Systems continues to lead the charge in providing industry cloud solutions for life sciences, utilizing innovative software, artificial intelligence, and consulting services. With over 1,500 clients, ranging from major pharmaceutical giants to emerging biotech firms, Veeva remains committed to the success of its customers alongside its public benefit objectives.
As with all acquisitions, Veeva acknowledges the associated risks and uncertainties, with Veeva CFO encouraging stakeholders to consult periodic SEC filings for detailed information regarding potential implications.
For further details, representatives from Veeva's communication team, Maria Scurry and Meera Lakhani-Patel, are available to discuss the broader impacts of this acquisition and rollout, establishing Veeva Falcon MLR as a revolutionary tool in the life sciences content review landscape.
Overall, with the merger of Veeva and Copli, the company is well poised to redefine the speed and efficiency of content review in the life sciences sector, solidifying its role as an integral player in the industry's future advancements.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.